Kincell Bio Advances Moonlight Bio’s T Cell Candidate

Kincell Bio, a US cell therapy CDMO, entered a partnership with Moonlight Bio, Inc., a Seattle-based biotech company pioneering advanced T cell therapies for solid tumors. In this partnership, Kincell provides CMC development and GMP manufacturing services to advance Moonlight’s lead T cell therapy program into clinical trials.

Kincell is providing process and analytical transfer, and GMP manufacturing services, to support the scale-up and clinical supply of Moonlight’s lead T cell therapy product. The collaboration between Moonlight and Kincell is designed to accelerate clinical supply and meet the needs of patients, advancing Kincell’s mission to support innovators in the rapidly growing cell therapy sector.

“At Moonlight, we are dedicated to delivering T cell therapies that address barriers obstructing successful outcomes in solid tumors – the vast majority of the global cancer disease burden,” said Jordan Jarjour, PhD, Moonlight’s CSO. “We are very excited to collaborate with Kincell to advance our lead program into the clinic.”